12 min read
TL;DR: – Hormone therapy (HRT/MHT) is the administration of exogenous hormones to compensate for declining natural production, most commonly during menopause or hypogonadism.
- The 2022 NAMS position statement concludes that for healthy women under 60 or within 10 years of menopause, benefits outweigh risks – a major shift from post-2002 guidance.
- Transdermal estrogen carries no increased blood clot risk, unlike oral estrogen; delivery method matters as much as hormone type.
- Combined HRT adds approximately 8 breast cancer cases per 10,000 women per year – substantially less than obesity's 30+ additional cases.
What Is Hormone Therapy?
Hormone therapy (HRT/MHT) refers to the administration of exogenous hormones to compensate for declining endogenous hormone production, most commonly in menopause or hypogonadism. It's not a one-size-fit-all treatment – it's a category of therapies tailored to individual hormone deficiencies and symptoms.
Hormones regulate virtually every major body system including cardiovascular, neurological, metabolic, musculoskeletal, and reproductive functions. When estrogen, progesterone, or testosterone decline – whether naturally or surgically – the cascade of symptoms can be profound: hot flashes, night sweats, mood instability, cognitive fog, bone loss, and sexual dysfunction.
Approximately 40% to 60% of women seek treatment for menopause symptoms, while 20% may delay treatment for over a year. The decision to pursue hormone therapy isn't trivial. It requires understanding your candidacy, weighing benefits against risks in your specific context, and choosing a delivery method that fits your lifestyle and health profile.
Key Takeaway: Hormone therapy compensates for declining natural hormone production. It's most effective for vasomotor symptoms (hot flashes, night sweats) and bone health, with benefits that vary by age, timing, and individual risk factors.
What Are the Main Types of Hormone Therapy?
Hormone therapy isn't monolithic. The type you're prescribed depends on which hormones you're deficient in, your surgical history, and your symptom profile. Here's the landscape:
| Type | Primary Use | Common Forms | Typical Candidate |
|---|---|---|---|
| Menopausal HT (Estrogen-only) | Vasomotor symptoms, bone loss (post-hysterectomy) | Patch, gel, cream, pill | Women without a uterus |
| Menopausal HT (Combined E+P) | Vasomotor symptoms, bone loss, mood (with uterus) | Patch + micronized progesterone, combined pill | Women with intact uterus |
| Testosterone Replacement (TRT) | Low libido, fatigue, muscle loss, mood (men & women) | Gel, cream, injection, pellet | Men with hypogonadism; women with low testosterone |
| Thyroid Hormone | Hypothyroidism, fatigue, metabolism | Levothyroxine (synthetic), desiccated thyroid | Patients with low TSH or thyroid dysfunction |
| Bioidentical (BHRT) | Same as above, but molecularly identical to human hormones | Patches, gels, creams, pellets, compounded | Patients preferring body-identical formulations |
Menopausal Hormone Therapy (MHT)
MHT replenishes women with ovarian hormones diminished during the natural menopausal transition to alleviate associated symptoms, especially hot flashes and night sweats. The choice between estrogen-only and combined therapy hinges on whether you still have a uterus.
Estrogen-only therapy is reserved for women post-hysterectomy. In the estrogen-alone trial, there was a lower incidence of breast cancer in the CEE group vs placebo (HR, 0.77; 95% CI, 0.62-0.95) during the intervention period. This counter-intuitive finding – that estrogen alone may reduce breast cancer risk – is rarely discussed in lay coverage but important for candidacy decisions.
Combined estrogen-progestin therapy is standard for women with an intact uterus, as progesterone protects the endometrium from unopposed estrogen stimulation. Results showed a significant reduction in vasomotor symptoms for the estrogen-plus-progestin groups (OR, 0.38; 95% CI, 0.25–0.58) compared to placebo.
Testosterone Replacement Therapy (TRT)
Testosterone therapy in women has been shown to improve sexual function, including desire, arousal, and pleasure, in randomized controlled trials, though no testosterone product is currently FDA-approved specifically for low libido in women. Off-label use is common and evidence-supported.
For men, testosterone treatment of men with hypogonadism significantly increased sexual desire, physical function, bone density, and mood, with the largest benefit for sexual function. The Testosterone Trials (T-Trials) – seven coordinated randomized controlled trials – established TRT's efficacy in men over 65 with documented hypogonadism.
Bioidentical Hormone Therapy
The optimal type of HRT is body identical HRT – the hormones are the same as the hormones you naturally produce in your body. The optimal oestrogen in HRT is a type of oestrogen called '17 beta oestradiol'. This is a body identical estrogen and has the same molecular structure as the estrogen which decreases in your body during the menopause.
Here's the critical distinction: FDA-approved hormone products containing bioidentical hormones include estradiol patches, estradiol gels, and micronized progesterone. Custom-compounded bioidentical hormones are not FDA-approved and have not been shown to be safer or more effective than FDA-approved hormone therapy. Up to 2.5 million US women aged 40 years or older may use compounded hormone therapy accounting for 28% to 68% of hormone prescriptions.
Compounded BHRT is popular but unregulated. FDA-approved bioidentical products (like estradiol patches) offer standardized dosing and safety data.
Key Takeaway: Estrogen-only HT is for post-hysterectomy women; combined E+P is standard with an intact uterus. Bioidentical hormones are molecularly identical to human hormones, but FDA-approved versions (patches, gels) carry more safety data than compounded options.
Who Is a Good Candidate for Hormone Therapy?
Candidacy isn't determined by age alone – it's a constellation of symptoms, lab values, and risk factors. Here's what providers evaluate:
Symptoms that suggest you may benefit:
- Hot flashes or night sweats (most responsive to HT)
- Sleep disturbance or insomnia
- Mood instability, anxiety, or depression
- Vaginal dryness or sexual dysfunction
- Joint or muscle aches
- Cognitive fog or memory issues
- Bone loss (osteopenia/osteoporosis)
Key lab markers:
- FSH (follicle-stimulating hormone): elevated in menopause
- LH (luteinizing hormone): elevated in menopause
- Estradiol: low in menopause
- Total and free testosterone: low in hypogonadism
- TSH: rules out thyroid dysfunction
- Comprehensive metabolic panel: baseline liver/kidney function
The timing window matters. For healthy women under 60 who are within ten years of menopause onset, the benefits of hormone therapy outweigh the risks. This "window of opportunity" is central to modern HT prescribing. Women who initiate therapy early see cardiovascular benefit; those starting after 60 or 10+ years past menopause face a different risk-benefit profile.
Absolute contraindications (do not use systemic HT):
- Personal history of hormone-sensitive breast cancer
- Unexplained vaginal bleeding
- Active thromboembolic disease (DVT, PE, stroke)
- Active liver disease
- Known thrombophilia (Factor V Leiden, etc.)
Relative contraindications (use with caution or alternative routes):
- Prior VTE (transdermal estrogen may be safer than oral)
- Migraine with aura (estrogen can trigger strokes)
- Uncontrolled hypertension
- Active smoking (increases VTE risk with oral estrogen)
Local vaginal estrogen has a different contraindication profile – it's appropriate for many women who cannot use systemic therapy.
Key Takeaway: Candidacy hinges on symptom severity, lab confirmation, age (ideally under 60), timing (within 10 years of menopause), and absence of contraindications. The "window of opportunity" is critical: early initiation is cardioprotective; late initiation carries higher cardiovascular risk.
What Are the Benefits and Risks of Hormone Therapy?
This is where the confusion lives. The 2002 Women's Health Initiative (WHI) study terrified millions of women away from HT. But the WHI had a fatal flaw: The average age of women in the study was 63 years — over a decade past the average age of a woman experiencing menopause. The findings don't apply to younger, recently menopausal women.
Evidence-Based Benefits
Vasomotor symptom relief. Up to 70 – 80% of women experiencing vasomotor symptoms (hot flashes and/or night sweats). HT is the most effective treatment for the relief of vasomotor symptoms (VMS). You should notice that your symptoms begin to improve within one to three months.
Bone health. Women can lose up to 20 percent of bone density in the first five to seven years after menopause. HT slows this loss significantly and reduces fracture risk.
Cardiovascular benefit (if started early). Randomized studies show that women who initiate HRT within 10 years of the onset of menopause (generally before age 60) have a reduction in all-cause mortality and fractures. Women may also reduce their risk of cardiovascular diseases by as much as 50%, Alzheimer's disease by 35%, and bone fractures by 50 to 60%.
Mood and cognitive function. Estrogen supports serotonin and dopamine signaling. Many women report improved mood, anxiety reduction, and clearer thinking within 8–12 weeks.
Known Risks and How to Contextualize Them
Breast cancer risk. This is the headline that stops women cold. The relative risk of breast cancer for current users of combined HRT was 2.00 (95% CI 1.88–2.12). In absolute terms, the excess breast cancer risk translates to approximately 8 additional cases per 10,000 women per year of use.
Here's the context: Postmenopausal obesity is associated with a 30–50% increased risk of breast cancer, which in absolute terms exceeds the excess risk associated with 5 years of combined MHT use. Daily alcohol use adds 10+ cases per 10,000 women per year. The risk is real but modest in absolute terms, and it declines after stopping HT.
Venous thromboembolism (blood clots). People who used HRT tablets were 58% more likely to develop a blood clot within 90 days than those who did not use HRT. But here's the critical distinction: Individuals who used HRT absorbed through the skin, such as gels, patches, or creams, had no increased risk of blood clots. Delivery method is everything.
Stroke. Oral estrogen carries a modest increased stroke risk, especially in women over 60 or with migraine with aura. Transdermal estrogen carries less risk.
Key Takeaway: HT's benefits (vasomotor relief, bone health, cardiovascular protection if started early) are substantial for eligible women. Risks (breast cancer +8/10,000/year, VTE with oral estrogen, stroke) are real but modest in absolute terms and heavily influenced by age, timing, and delivery method.
How Does Hormone Therapy Work in Practice?
Understanding the mechanics helps you set realistic expectations and choose the right delivery method.
Delivery methods and their trade-offs:
| Route | Pros | Cons | VTE Risk |
|---|---|---|---|
| Transdermal patch | No first-pass liver metabolism; stable levels; low VTE risk | Skin irritation; less convenient than pills | None |
| Gel/cream | Flexible dosing; good absorption; low VTE risk | Messy; transfer risk to others | None |
| Oral pill | Convenient; familiar | First-pass liver metabolism; higher VTE risk; variable absorption | 2–4× elevated |
| Injection (IM) | Predictable dosing; long-acting | Requires clinic visits; injection anxiety | Low |
| Pellet (subcutaneous) | 3–6 month dosing; steady levels | Requires minor surgery; difficult to adjust; cost | Low |
Timeline for symptom improvement:
- Hot flashes: 4 weeks
- Sleep quality: 6–8 weeks
- Mood, cognitive function: 8–12 weeks
- Bone density: 6–12 months
Monitoring and follow-up: Most providers check in at 4–6 weeks to assess symptom response and side effects, then every 6–12 months. Lab retesting (FSH, estradiol, testosterone) is typically done annually or when adjusting doses.
Stopping HT: Abrupt discontinuation can trigger rebound hot flashes. Most providers recommend tapering over 3–6 months, reducing dose by 25% every 4–6 weeks.
Cost context: Generic estradiol patches cost approximately $30–$60/month at most pharmacies; compounded bioidentical creams from specialty pharmacies typically run $100–$300/month. Insurance coverage varies widely; compounded BHRT is rarely covered.
Key Takeaway: Transdermal delivery (patches, gels) avoids first-pass liver metabolism and carries no VTE risk, unlike oral estrogen. Symptom improvement takes 4–12 weeks depending on the symptom. Generic options cost $30–60/month; compounded bioidentical options cost $100–300/month.
Can Integrative Approaches Complement Hormone Therapy?
Hormone therapy isn't an either-or proposition. Evidence-based lifestyle and nutritional strategies can enhance outcomes and sometimes reduce required hormone doses.
Strength training and resistance exercise. Resistance exercise training significantly reduced vasomotor symptoms and improved body composition in postmenopausal women; combined with HRT, it produced additive benefits on lean mass and bone density. Aim for 2–3 sessions weekly of compound movements (squats, deadlifts, rows).
Nutrition and metabolic support.
- Phytoestrogen-rich foods (flaxseeds, legumes, soy) provide mild estrogenic activity and may reduce hot flash frequency.
- Blood sugar stability (whole grains, protein, healthy fats) reduces cortisol spikes that exacerbate vasomotor symptoms.
- Adequate calcium and vitamin D support bone health alongside HT.
Stress and sleep optimization.
- Chronic stress elevates cortisol, which antagonizes estrogen's effects.
- Sleep deprivation worsens hot flashes and mood instability.
- Meditation, yoga, and CBT have Level 1 evidence for reducing hot flash frequency and distress.
Functional medicine testing. Integrative providers often assess beyond standard labs: cortisol patterns (4-point saliva test), micronutrient status (B vitamins, magnesium, iron), thyroid antibodies (Hashimoto's), and gut dysbiosis markers. These reveal root causes of fatigue, mood issues, and poor HT response.
Providers like those at Home – S.I.E.M. blend integrative and naturopathic medicine to optimize long-term wellness through personalized care and advanced testing. This approach identifies metabolic and nutritional gaps that may be limiting your response to hormone therapy, allowing for lower effective doses and better overall outcomes.
Key Takeaway: Strength training, blood sugar stability, stress management, and functional medicine testing can enhance HT outcomes and potentially reduce required hormone doses. These adjuncts don't replace systemic HT for severe vasomotor symptoms but meaningfully improve quality of life.
Frequently Asked Questions About Hormone Therapy
How much does hormone therapy cost per month?
Direct Answer: Generic estradiol patches cost $30–$60/month; compounded bioidentical creams cost $100–$300/month. Oral estrogen and testosterone products range $20–$150/month depending on formulation and pharmacy.
Insurance coverage varies. Most plans cover FDA-approved HT products if medically necessary; compounded BHRT is rarely covered. GoodRx and similar discount programs can reduce out-of-pocket costs for generic options by 20–40%.
How long is it safe to stay on hormone therapy?
Direct Answer: Experts generally recommend that you get it at the lowest dose for the shortest time possible. Most guidelines support 5–7 years of use for symptom management, though some women benefit from longer-term therapy.
The key is periodic reassessment. Every 1–2 years, discuss with your provider whether you still need HT or if symptoms have resolved. Bone health and cardiovascular benefits may justify longer use in some women.
Is bioidentical hormone therapy safer than conventional HRT?
Direct Answer: FDA-approved bioidentical hormones (estradiol patches, micronized progesterone) have equivalent safety data to conventional HRT. Compounded bioidentical hormones lack rigorous safety testing and are not FDA-approved.
The distinction matters: a bioidentical estradiol patch is as safe as a conventional estradiol patch. A custom-compounded cream from a specialty pharmacy has no regulatory oversight. Choose FDA-approved bioidentical products if that's your preference.
What is the difference between hormone therapy and hormone replacement therapy?
Direct Answer: The terms are used interchangeably. "Hormone replacement therapy" (HRT) emphasizes replacing hormones lost during menopause. "Hormone therapy" (HT) is broader and includes testosterone therapy, thyroid therapy, and other hormonal treatments beyond menopause.
In modern usage, HRT typically refers to menopausal hormone therapy; HT is the umbrella term.
Can hormone therapy cause weight gain?
Direct Answer: Hormone therapy itself doesn't directly cause weight gain, but declining estrogen during menopause slows metabolism, making weight maintenance harder. HT can partially reverse this metabolic slowdown.
Some women report water retention or increased appetite on HT, particularly with oral formulations. Transdermal delivery and adequate strength training minimize this risk.
How do I start hormone therapy – what does the process look like?
Direct Answer: Schedule an appointment with a gynecologist, primary care physician, or menopause specialist. Bring a symptom log (hot flash frequency, sleep quality, mood) and your medical/family history.
Your provider will order labs (FSH, estradiol, TSH, metabolic panel), review contraindications, and discuss options. If you're a candidate, you'll start on a low dose and adjust at 4–6 week follow-ups based on symptom response and side effects.
What are the alternatives to hormone therapy for menopause symptoms?
Direct Answer: Non-hormonal prescription options include venlafaxine (SNRI, ~60% hot flash reduction), paroxetine (SSRI), and fezolinetant (Veozah, FDA-approved May 2023). Cognitive Behaviour Therapy targeting hot flushes significantly reduced hot flash problem rating and frequency in randomized trials, with benefits maintained at 6-month follow-up.
Lifestyle adjuncts (strength training, stress management, phytoestrogen-rich diet) provide modest benefit. For women with contraindications to HT, integrative approaches combined with non-hormonal medications offer meaningful relief.
Ready to Get Started?
For personalized guidance, visit Home – S.I.E.M. to learn how we can help.
Conclusion
The 18-year WHI follow up data showed no difference in cause specific mortality or all-cause mortality in women treated with HT vs. placebo and indicated favorable trends for all-cause mortality among the younger women treated with oCEE alone. Prescriptions for hormone therapy have increased 72% since 2021, reflecting a shift back toward evidence-based practice.
The decision to pursue HT is personal and nuanced. It depends on your age, symptom severity, risk factors, and preferences. If you're experiencing moderate-to-severe vasomotor symptoms, bone loss, or hormonal imbalance, a conversation with a qualified provider is warranted.
For those seeking a comprehensive, integrative approach that combines conventional medicine with functional assessment, Home – S.I.E.M. offers personalized hormone evaluation and optimization. Their integrative model identifies root causes of hormonal dysfunction and tailors therapy to your individual metabolism and health goals – bridging conventional HT with lifestyle and nutritional support for optimal outcomes.
The evidence is clear: hormone therapy, when appropriately prescribed to eligible candidates, offers substantial benefits with manageable risks. The window of opportunity is real. Don't let outdated fear-mongering keep you from relief.